KNTE Stock Overview
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kinnate Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.65 |
| 52 Week High | US$7.19 |
| 52 Week Low | US$1.04 |
| Beta | 1.34 |
| 11 Month Change | 2.32% |
| 3 Month Change | 6.43% |
| 1 Year Change | -56.84% |
| 33 Year Change | -90.86% |
| 5 Year Change | n/a |
| Change since IPO | -93.21% |
Recent News & Updates
Recent updates
Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?
Jun 11
We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely
Jan 04FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor
Sep 21Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans
Sep 15Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03
Aug 11We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely
May 15Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth
Jan 24We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth
Oct 09Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation
Jun 22We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate
Mar 03Kinnate Biopharma earns bulls as IPO quiet period ends
Dec 28Shareholder Returns
| KNTE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.4% | 4.3% | 1.6% |
| 1Y | -56.8% | 18.8% | 32.3% |
Return vs Industry: KNTE underperformed the US Biotechs industry which returned 7.6% over the past year.
Return vs Market: KNTE underperformed the US Market which returned 25.7% over the past year.
Price Volatility
| KNTE volatility | |
|---|---|
| KNTE Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KNTE has not had significant price volatility in the past 3 months.
Volatility Over Time: KNTE's weekly volatility has decreased from 14% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 94 | Nima Farzan | www.kinnate.com |
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Kinnate Biopharma Inc. Fundamentals Summary
| KNTE fundamental statistics | |
|---|---|
| Market cap | US$125.15m |
| Earnings (TTM) | -US$112.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs KNTE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNTE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$112.65m |
| Earnings | -US$112.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.39 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KNTE perform over the long term?
See historical performance and comparison